Özbey N et al (2006) Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg 30:321–326

Article  PubMed  Google Scholar 

Untch BR et al (2007) Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 142:1022–1026

Article  PubMed  Google Scholar 

Priya G et al (2008) Clinical and laboratory profile of primary hyperparathyroidism in India. Postgrad Med J 84:34–39

Article  PubMed  Google Scholar 

Lang BHH, Lo CY (2010) Vitamin D3 deficiency is associated with late-onset hypocalcemia after minimally invasive parathyroidectomy in a vitamin D borderline area. World J Surg 34:1350–1355

Article  PubMed  Google Scholar 

Rolighed L et al (2014) Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab 99:1072–1080

Article  PubMed  Google Scholar 

Bilezikian JP et al (2022) Management of Primary Hyperparathyroidism. J Bone Miner Res 37:2391–2403

Article  PubMed  Google Scholar 

Kabadi UM (2020) Low 25-Hydroxyvitamin D in primary hyperparathyroidism: enhanced conversion into 1,25-hydroxyvitamin D may not be ‘true’ deficiency. JBMR plus 4:e10415

Article  PubMed  PubMed Central  Google Scholar 

Song A et al (2021) Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis. J Endocrinol Invest 44:1667–1677

Article  PubMed  Google Scholar 

Holick MF et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930

Article  PubMed  Google Scholar 

Shimada T et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435

Article  PubMed  Google Scholar 

Walton RJ, Bijvoet OLM (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet (London, England) 2:309–310

Article  PubMed  Google Scholar 

Goltzman D, Mannstadt M, Marcocci C (2018) Physiology of the calcium-parathyroid hormone-vitamin D axis. Front Horm Res 50:1–13

Article  PubMed  Google Scholar 

Singh RJ, Kumar R (2003) Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc 78:826–829

Article  PubMed  Google Scholar 

Yamashita H et al (2004) Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 151:55–60

Article  PubMed  Google Scholar 

Tebben PJ, Singh RJ, Clarke BL, Kumar R (2004) Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 79:1508–1513

Article  PubMed  Google Scholar 

Witteveen JE, Van Lierop AH, Papapoulos SE, Hamdy NAT (2012) Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? Eur J Endocrinol 166:55–60

Article  PubMed  Google Scholar 

Kobayashi K et al (2006) Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 154:93–99

Article  PubMed  Google Scholar 

Nagata Y et al (2019) Attenuated dentin matrix protein 1 enhances fibroblast growth factor 23 in calvaria in a primary hyperparathyroidism model. Endocrinology 160:1348–1358

Article  PubMed  Google Scholar 

Nagata Y et al (2022) Parathyroid hormone regulates circulating levels of sclerostin and FGF23 in a primary hyperparathyroidism model. J Endocr Soc 6:1–10

Article  Google Scholar 

Alshayeb H et al (2014) Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol. J Clin Endocrinol Metab 99:E1830–E1837

Article  PubMed  PubMed Central  Google Scholar 

Nygaard B et al (2014) Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial. PLoS One 9:e102965

Article  PubMed  PubMed Central  Google Scholar 

Kamelian T, Saki F, Jeddi M, Dabbaghmanesh MH, Omrani GHR (2018) Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial. J Endocrinol Invest 41:299–306

Article  PubMed  Google Scholar 

Charoenngam N, Rujirachun P, Holick MF, Ungprasert P (2019) Oral vitamin D3 supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients: a systematic review and meta-analysis. Osteoporos Int 30:2183–2193

Article  PubMed  Google Scholar 

Zittermann A, Berthold HK, Pilz S (2021) The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr 75:980–987

Article  PubMed  Google Scholar 

Ratsma DMA, Muller M, Koedam M, Zillikens MC, van der Eerden BCJ (2023) In vitro regulation of fibroblast growth factor 23 by 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D synthesized by osteocyte-like MC3T3-E1 cells. Eur J Endocrinol 189:448–459

Article  PubMed  Google Scholar 

De Niet S et al (2018) A randomized study to compare a monthly to a daily administration of vitamin D3 supplementation. Nutrients 10:659

Article  PubMed  PubMed Central  Google Scholar 

Zittermann A, Ernst JB, Birschmann I, Dittrich M (2015) Effect of vitamin D or activated vitamin D on circulating 1,25-dihydroxyvitamin D concentrations: a systematic review and metaanalysis of randomized controlled trials. Clin Chem 61:1484–1494

Article  PubMed  Google Scholar 

Trummer C et al (2017) Effects of vitamin D supplementation on IGF-1 and calcitriol: a randomized-controlled trial. Nutrients 9:623

Article  PubMed  PubMed Central  Google Scholar 

Okai GG et al (2022) LC-MS/MS reduces interference by high levels of 25(OH)D and its metabolites on measured 1,25(OH)2D. Steroids 187:109095

Article  PubMed  Google Scholar 

Martineau AR et al (2019) Differential effects of oral boluses of vitamin D2 vs vitamin D3 on vitamin D metabolism: a randomized controlled trial. J Clin Endocrinol Metab 104:5831–5839

Article  PubMed  PubMed Central  Google Scholar 

Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF (2013) Serum concentrations of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation. J Clin Endocrinol Metab 98:973–979

Article  PubMed  PubMed Central  Google Scholar 

Bislev LS et al (2018) The effect of vitamin D3 supplementation on markers of cardiovascular health in hyperparathyroid, vitamin D insufficient women: a randomized placebo-controlled trial. Endocrine 62:182–194

Article  PubMed  Google Scholar 

Stubbs JR, Zhang S, Friedman PA, Nolin TD (2014) Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD. Clin J Am Soc Nephrol 9:1965–1973

Article  PubMed  PubMed Central  Google Scholar 

Castellano E et al (2017) Nephrolithiasis in primary hyperparathyroidism: a comparison between silent and symptomatic patients. Endocr Pract 23:157–162

Article  PubMed  Google Scholar 

Isidro ML, Ruano B (2009) Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 36:305–310

Article  PubMed  Google Scholar 

Corbetta S et al (2005) Risk factors associated to kidney stones in primary hyperparathyroidism. J Endocrinol Invest 28:122–128

Article